m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03082)
Name
Naringenin
Synonyms
naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C15H12O5
InChI
1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2
InChIKey
FTVWIRXFELQLPI-UHFFFAOYSA-N
PubChem CID
932
TTD Drug ID
D02ABO
VARIDT Drug ID
DR00833
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aromatase (CYP19A1) is a therapeutic target for Naringenin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Naringenin through regulating the expression of Aromatase (CYP19A1). [1], [2]
Cytochrome P450 1B1 (CYP1B1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Naringenin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Naringenin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Naringenin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naringenin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [4], [5]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Naringenin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Naringenin through regulating the expression of P-glycoprotein 1 (ABCB1). [6], [7]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Naringenin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naringenin through regulating the expression of P-glycoprotein 1 (ABCB1). [7], [8]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity. J Med Chem. 2008 Jul 24;51(14):4226-38. doi: 10.1021/jm800168s. Epub 2008 Jul 1.
Ref 3 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
Ref 4 Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. doi: 10.1016/j.bmc.2010.07.020. Epub 2010 Jul 13.
Ref 5 METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation. Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F839-F847. doi: 10.1152/ajprenal.00222.2020. Epub 2020 Sep 21.
Ref 6 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 7 Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
Ref 8 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.